Pilot Study of Time-Restricted, Intermittent Fasting for Non-Alcoholic Fatty Liver Disease in Non-Obese Adults
NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\<30kg/m2) is an increasingly recognized condition, sometimes described as lean NAFLD. Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.
• Willing and able to provide informed consent
• Age 18 years or older at time of consent
• BMI 23-30kg/m\^2 at screening
• Evidence of NAFLD confirmed by historical procedure obtained no more than 6 months prior to the screening visit, defined as:
‣ Grade \>=1 steatosis on clinical liver biopsy; OR
⁃ Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound)
• Liver fat fraction ≥10% on H-MRS performed during the screening period
• Hepatitis C antibody and Hepatitis B surface antigen negative at screening